AFFINITY 20U ARTERIAL FILTER WITH TRILLIUM BIOSURFACE

K033468 · Medtronic Perfusion Systems · DTM · Nov 14, 2003 · Cardiovascular

Device Facts

• Record ID: K033468
• Device Name: AFFINITY 20U ARTERIAL FILTER WITH TRILLIUM BIOSURFACE
• Applicant: Medtronic Perfusion Systems
• Product Code: DTM · Cardiovascular
• Decision Date: Nov 14, 2003
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 870.4260
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The AFFINITY® 20 µ Arterial Blood Filter with Trillium™ Biosurface is indicated for use in cardiopulmonary bypass procedures up to 6 hours in duration for the removal of particulate and gaseous microemboli.

Device Story

Single-use arterial blood filter for extracorporeal circuits during cardiopulmonary bypass surgery; removes particulate and gaseous microemboli from blood. Device features Trillium™ biosurface coating on blood-contacting surfaces to improve hemocompatibility. Operated by perfusionists or surgical staff in clinical settings. Output is filtered blood returned to patient; benefits include reduced risk of embolic complications during bypass.

Clinical Evidence

Bench testing only. In vitro testing evaluated coating characteristics, physical characteristics, and performance characteristics to demonstrate substantial equivalence to predicate devices.

Technological Characteristics

Arterial line blood filter (21 CFR 870.4260); single-use; incorporates Trillium™ nonleaching biosurface coating on blood-contacting surfaces. Mechanical filtration principle.

Indications for Use

Indicated for patients undergoing cardiopulmonary bypass procedures (up to 6 hours) requiring removal of particulate and gaseous microemboli.

Regulatory Classification

Identification

A cardiopulmonary bypass arterial line blood filter is a device used as part of a gas exchange (oxygenator) system to filter nonbiologic particles and emboli (blood clots or pieces of foreign material flowing in the bloodstream which will obstruct circulation by blocking a vessel) out of the blood. It is used in the arterial return line.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Arterial Line Blood Filter 510(k) Submissions.”

Predicate Devices

• AFFINITY® 20 µ Arterial Blood Filter (K994208)
• AFFINITY® Hollow Fiber Oxygenator with Trillium™ Biosurface (K973760)

Submission Summary (Full Text)

{0}------------------------------------------------

## SUMMARY OF SAFETY AND EFFECTIVENESS

#### COMPANY AND CONTACT PERSON

Medtronic Perfusion Systems 7611 Northland Drive Minneapolis, MN 55428 Tel: [phone] FAX: [phone]

Michele Pyfferoen, Requlatory Affairs Specialist, Requlatory Affairs

### DEVICE NAME

AFFINITY® 20 µ Arterial Blood Filter with Trillium™ Biosurface

### NAME OF PREDICATED OR LEGALLY MARKETED DEVICE

AFFINITY® 20 µ Arterial Blood Filter (K994208) AFFINITY® Hollow Fiber Oxygenator with Trillium™ Biosurface (K973760)

### DESCRIPTION OF DEVICE

The AFFINITY® 20 µ Arterial Blood Filter with Trillium™ Biosurface is a single use device designed to filter microemboli from the blood in the extracorporeal circuits during cardiopulmonary bypass surgery.

The AFFINITY 20 µ Arterial Blood Filter with Trillium" Biosurface is coated with a nonleaching biosurface.

## STATEMENT OF INTENDED USE

The AFFINITY® 20 µ Arterial Blood Filter with Trillium™ Biosurface is indicated for use in cardiopulmonary bypass procedures up to 6 hours in duration for the removal of particulate and gaseous microemboli.

#### STATEMENT OF INTENDED USE OF PREDICATED/MARKETED DEVICE

The AFFINITY® 20 µ Arterial Blood Filter is indicated for use in cardiopulmonary bypass procedures up to 6 hours in duration for the removal of particulate and gaseous microemboli.

## STATEMENT OF TECHNOLOGICAL CHARACTERISTICS COMPARISON

Information regarding technological characteristics comparison is provided in the following section, "Determination of Substantial Equivalence".

{1}------------------------------------------------

## DETERMINATION OF SUBSTANTIAL EQUIVALENCE

This "SPECIAL 510(k)" is being submitted for a modification to the AFFINITY® 20 µ Arterial Blood Filter. The modification to the current AFFINITY® 20 µ Arterial Blood Filter is to coat the blood contact surfaces with Trillium".

The AFFINITY®20 µ Arterial Blood Filter with Trillium™ Biosurface is being compared to the following Marketed Devices:

- AFFINITY® 20 u Arterial Blood Filter (K994208) .
- AFFINITY® Hollow Fiber Oxygenator with Trillium™ Biosurface (K973760) ●

The AFFINITY® 20 µ Arterial Blood Filter with Trillium™ Biosurface Trillium™ has the same indications statement and intended uses as the:

- AFFINITY® 20 µ Arterial Blood Filter (K994208) .
The AFFINITY® 20 µ Arterial Blood Filter with Trillium™ Biosurface has "no new technological characteristics (e.g., materials and manufacturing processes)" from the AFFINITY® 20 µ Arterial Blood Filter. The technological characteristic is solely the coating material of the blood contact surface:

- Trillium™ .
The technological characteristic of the Trillium™ Biosurface is common to other medical devices (hollow fiber oxygenators) currently in commercial distribution as follows:

- AFFINITY® Hollow Fiber Oxygenator with Trillium™ Biosurface (K973760) .
This technological characteristic "could affect the safety and effectiveness of the device". However, these "technological characteristics do not raise new types of safety or effectiveness questions". In addition, "there are acceptable scientific methods which exist for assessing effects of these new technological characteristics".

"Performance data to assess the effects of these new technological characteristics" has been performed. These "performance data demonstrate" that the AFFINITY" 20 µ Arterial Blood Filter with Trillium™ Biosurface is substantially equivalent to other marketed arterial filters.

The biocompatibility and in vitro bench testing demonstrated that when compared to the predicate devices, the AFFINITY® 20 µ Arterial Blood Filter with Trillium™ Biosurface does not significantly affect safety and effectiveness and are substantially equivalent to other commercially distributed arterial filters. The in vitro bench testing included analysis of:

- Coating Characteristics .
- Physical Characteristics .
- . Performance Characteristics

| Special 510 (k) Notification | AFFINITY® 20 μ Arterial Filter with | Confidential |
|------------------------------|-------------------------------------|--------------|
| Medtronic, Inc. | Trillium™ Biosurface | Page 17 |
| Medtronic Perfusion Systems | | |

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal is circular and features the department's name around the perimeter. In the center of the seal is an emblem of an eagle with its wings spread, symbolizing the department's mission to protect the health of all Americans and provide essential human services.

Public Health Service

NOV 1 4 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Medtronic Perfusion Systems c/o Ms. Michele Pyfferoen 7611 Northland Drive Minneapolis, MN 55428

Re: K033468

AFFINITY® 20μ Arterial Filter with Trillium™ Biosurface Regulation Number: 21 CFR 870.4260 Regulation Name: Cardiopulmonary Bypass Arterial Line Blood Filter Regulatory Class: Class II (two) Product Code: 74 DTM Dated: October 31, 2003 Received: November 3, 2003

Dear Ms. Pyfferoen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

#### Page 2 - Ms. Michele Pyfferoen

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckernan, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

510(k) Number (if known) K 033468

Device Name:

# AFFINITY® 20μ Arterial Filter with Trillium™ Biosurface

Indications for Use:

The AFFINITY® Arterial Filter with Trillium™ Biosurface is indicated for use in cardiopulmonary bypass procedures up to 6 hours in duration for the removal of particulate and gaseous microemboli.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

O.M.

vascular Devices

Ko 33468 510(k) Number

(Optional Format 3-10-98)